|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MYL4 |
Gene summary for MYL4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MYL4 | Gene ID | 4635 |
| Gene name | myosin light chain 4 | |
| Gene Alias | ALC1 | |
| Cytomap | 17q21.32 | |
| Gene Type | protein-coding | GO ID | GO:0002026 | UniProtAcc | P12829 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4635 | MYL4 | male-WTA | Human | Thyroid | PTC | 1.61e-07 | 5.39e-02 | 0.1037 |
| 4635 | MYL4 | PTC01 | Human | Thyroid | PTC | 4.27e-05 | 1.97e-01 | 0.1899 |
| 4635 | MYL4 | PTC05 | Human | Thyroid | PTC | 2.15e-04 | 2.22e-01 | 0.2065 |
| 4635 | MYL4 | PTC06 | Human | Thyroid | PTC | 1.31e-14 | 7.93e-01 | 0.2057 |
| 4635 | MYL4 | PTC07 | Human | Thyroid | PTC | 1.29e-08 | 3.31e-01 | 0.2044 |
| 4635 | MYL4 | ATC2 | Human | Thyroid | ATC | 1.79e-02 | 7.47e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00434629 | Thyroid | PTC | regulation of ATPase activity | 23/5968 | 46/18723 | 7.89e-03 | 3.33e-02 | 23 |
| GO:00327817 | Thyroid | PTC | positive regulation of ATPase activity | 15/5968 | 27/18723 | 9.19e-03 | 3.79e-02 | 15 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MYL4 | SNV | Missense_Mutation | c.35N>T | p.Ala12Val | p.A12V | P12829 | protein_coding | tolerated_low_confidence(0.2) | benign(0) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| MYL4 | insertion | Frame_Shift_Ins | novel | c.346_347insCAGC | p.Phe116SerfsTer19 | p.F116Sfs*19 | P12829 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| MYL4 | insertion | In_Frame_Ins | novel | c.347_348insACTCGGGAGGCTGAGGCAGGAGAATTG | p.Phe116delinsLeuLeuGlyArgLeuArgGlnGluAsnCys | p.F116delinsLLGRLRQENC | P12829 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| MYL4 | SNV | Missense_Mutation | novel | c.20N>T | p.Glu7Val | p.E7V | P12829 | protein_coding | tolerated_low_confidence(0.2) | possibly_damaging(0.611) | TCGA-ZJ-AB0H-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| MYL4 | SNV | Missense_Mutation | c.194N>A | p.Arg65Gln | p.R65Q | P12829 | protein_coding | tolerated(0.08) | possibly_damaging(0.882) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
| MYL4 | SNV | Missense_Mutation | rs374127769 | c.419N>A | p.Arg140His | p.R140H | P12829 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| MYL4 | SNV | Missense_Mutation | rs146980908 | c.287N>A | p.Arg96His | p.R96H | P12829 | protein_coding | deleterious(0.04) | benign(0.003) | TCGA-G4-6586-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MYL4 | SNV | Missense_Mutation | rs375241929 | c.406N>A | p.Val136Met | p.V136M | P12829 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-EI-7004-01 | Colorectum | rectum adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | SD |
| MYL4 | SNV | Missense_Mutation | rs201579845 | c.200N>T | p.Pro67Leu | p.P67L | P12829 | protein_coding | tolerated(0.1) | probably_damaging(0.966) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MYL4 | SNV | Missense_Mutation | rs111293783 | c.374N>A | p.Arg125His | p.R125H | P12829 | protein_coding | deleterious(0) | possibly_damaging(0.886) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |